Taysha Gene Therapies, Inc. Stock-Based Compensation
Taysha Gene Therapies, Inc. (TSHA) reported Stock-Based Compensation of $11.36 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-11
- Taysha Gene Therapies, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $5.81M, a 82.13% increase year-over-year.
- Taysha Gene Therapies, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $5.55M, a 68.40% increase year-over-year.
- Taysha Gene Therapies, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $3.53M, a 9.73% increase year-over-year.
- Taysha Gene Therapies, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $3.29M, a 2.14% decline year-over-year.
- Taysha Gene Therapies, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $13.30M, a 1.49% increase from fiscal 2024.
- Taysha Gene Therapies, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $13.10M, a 65.76% increase from fiscal 2023.
- Taysha Gene Therapies, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $7.91M, a 56.19% decline from fiscal 2022.
- Taysha Gene Therapies, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $18.04M, a 0.78% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 0 month | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $5.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $11.36M 10-Q · filed 2026-08-11 | $14.89M derived: sum of 3 quarters · filed 2026-08-11 | $18.17M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2026-03-31 | $5.55M 10-Q · filed 2026-05-06 | $9.08M derived: sum of 2 quarters · filed 2026-05-06 | $12.36M derived: sum of 3 quarters · filed 2026-05-06 | $15.55M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-12-31 | $3.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $6.81M derived: sum of 2 quarters · filed 2026-03-19 | $10.00M derived: sum of 3 quarters · filed 2026-08-11 | $13.30M 10-K · filed 2026-03-19 | |
| 2025-09-30 | $3.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $6.47M derived: sum of 2 quarters · filed 2026-08-11 | $9.77M 10-Q · filed 2025-11-04 | $12.98M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-06-30 | $3.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $6.48M 10-Q · filed 2026-08-11 | $9.70M derived: sum of 3 quarters · filed 2026-08-11 | $13.06M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-03-31 | $3.29M 10-Q · filed 2026-05-06 | $6.51M derived: sum of 2 quarters · filed 2026-05-06 | $9.87M derived: sum of 3 quarters · filed 2026-05-06 | $13.20M derived: sum of 4 quarters · filed 2026-05-06 | |
| 2024-12-31 | $3.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $6.57M derived: sum of 2 quarters · filed 2026-03-19 | $9.90M derived: sum of 3 quarters · filed 2026-03-19 | $13.10M 10-K · filed 2026-03-19 | |
| 2024-09-30 | $3.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $6.69M derived: sum of 2 quarters · filed 2025-11-04 | $9.89M 10-Q · filed 2025-11-04 | $11.86M derived: sum of 4 quarters · filed 2025-11-04 | |
| 2024-06-30 | $3.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $6.53M 10-Q · filed 2025-08-12 | $8.50M derived: sum of 3 quarters · filed 2025-08-12 | $10.54M derived: sum of 4 quarters · filed 2025-08-12 | |
| 2024-03-31 | $3.20M 10-Q · filed 2025-05-15 | $5.17M derived: sum of 2 quarters · filed 2025-05-15 | $7.21M derived: sum of 3 quarters · filed 2025-05-15 | $9.43M derived: sum of 4 quarters · filed 2025-05-15 | |
| 2023-12-31 | $1.97M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $4.01M derived: sum of 2 quarters · filed 2025-02-26 | $6.23M derived: sum of 3 quarters · filed 2025-02-26 | $7.91M 10-K · filed 2025-02-26 | |
| 2023-09-30 | $2.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $4.26M derived: sum of 2 quarters · filed 2024-11-13 | $5.94M 10-Q · filed 2024-11-13 | $10.04M derived: sum of 4 quarters · filed 2024-11-13 | |
| 2023-06-30 | $2.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $3.90M 10-Q · filed 2024-08-12 | $8.00M derived: sum of 3 quarters · filed 2024-08-12 | $12.47M derived: sum of 4 quarters · filed 2024-08-12 | |
| 2023-03-31 | $1.68M 10-Q · filed 2024-05-14 | $5.78M derived: sum of 2 quarters · filed 2024-05-14 | $10.25M derived: sum of 3 quarters · filed 2024-05-14 | $14.39M derived: sum of 4 quarters · filed 2024-05-14 | |
| 2022-12-31 | $4.10M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $8.57M derived: sum of 2 quarters · filed 2024-03-19 | $12.71M derived: sum of 3 quarters · filed 2024-03-19 | $18.04M 10-K · filed 2024-03-19 | |
| 2022-09-30 | $4.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $8.61M derived: sum of 2 quarters · filed 2023-11-14 | $13.94M 10-Q · filed 2023-11-14 | $18.89M derived: sum of 4 quarters · filed 2023-11-14 | |
| 2022-06-30 | $4.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $9.47M 10-Q · filed 2023-08-14 | $14.43M derived: sum of 3 quarters · filed 2023-08-14 | $19.51M derived: sum of 4 quarters · filed 2023-08-14 | |
| 2022-03-31 | $5.33M 10-Q · filed 2023-05-11 | $10.28M derived: sum of 2 quarters · filed 2023-05-11 | $15.37M derived: sum of 3 quarters · filed 2023-05-11 | $19.92M derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | $4.96M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $10.04M derived: sum of 2 quarters · filed 2023-03-28 | $14.59M derived: sum of 3 quarters · filed 2023-03-28 | $18.18M 10-K · filed 2023-03-28 | |
| 2021-09-30 | $5.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $9.63M derived: sum of 2 quarters · filed 2022-11-08 | $13.23M 10-Q · filed 2022-11-08 | $15.24M derived: sum of 4 quarters · filed 2022-11-08 | |
| 2021-06-30 | $4.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $8.14M 10-Q · filed 2022-08-11 | $10.16M derived: sum of 3 quarters · filed 2022-08-11 | ||
| 2021-03-31 | $3.59M 10-Q · filed 2022-05-16 | $5.61M derived: sum of 2 quarters · filed 2022-05-16 | |||
| 2020-12-31 | $2.01M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $3.35M 10-K · filed 2022-03-31 | |||
| 2020-09-30 | $1.34M 10-Q · filed 2021-11-10 | ||||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-11 | $0.00 derived: sum of 2 quarters · filed 2021-05-11 | |||
| 2019-12-31 | $0.00 10-K · filed 2021-03-03 | ||||
| 2019-09-30 | $0.00 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |